Therapy Consortium EU-FP7. Composition and function of macroencapsulated human embryonic stem cell-derived implants: comparison with clinical human islet cell grafts.
Human embryonic stem (huES) cells are a potential source for grafts that restore a functional ␤-cell mass in type 1 patients. Several teams have generated insulin-positive cells from huES cells and studied their characteristics (1, 3-5, 8, 13, 18, 30) . Investigators at ViaCyte (San Diego, CA) have developed in vitro protocols for deriving pancreatic endodermal cells that further differentiate to ␤-cell-containing tissue following transplantation in the epididymal fat pad of immunedeficient mice (18) . Appearance of human C-peptide (huCpeptide) in plasma and its increase following glucose injection was indicative for development of functional ␤-cells. Using another huES cell source, investigators in Vancouver, BC, Canada, reproduced the differentiation to huC-peptide-releasing ␤-cells in implants under the kidney capsule currently in the hyperglycemic environment of streptozocin-diabetic mice (30) . This was also the case for subcutaneous implants in a TheraCyte macroencapsulation device (TheraCyte Laguna Hills, CA), but with low plasma huC-peptide levels and poor glucose responsiveness (2) . Later studies showed formation of glucose-responsive ␤-cells when only the NKX6.1-enriched fraction was implanted (31) . The appearance of plasma huCpeptide levels, increasing after glucose injection with a decrease in glycemia, is in itself insufficient evidence for formation of metabolically adequate ␤-cells, a requirement to qualify for ␤-cell replacement. Rapid responsiveness to increases or decreases in glucose concentrations has not yet been demonstrated but is an essential property in terms of both efficacy and safety. To examine this property, we compared the secretory responses of perifused huES cell-derived ␤-cells and human islet cell isolates, as used in our clinical transplant program (14) . The ability to quantitatively retrieve implants from a macroencapsulation device makes such analysis technically feasible and biologically representative as well as clinically relevant in view of plans to use this route in clinical studies. However, it was necessary to first compare the in vivo outcome of macroencapsulated implants with that of nonencapsulated or microencapsulated ones of similar size. This comparative analysis showed earlier and higher huC-peptide levels in the plasma of macroencapsulated recipients, which supported the use of these implants for investigating the in vitro secretory properties of huES cell-derived ␤-cells. Data were interpreted in light of the insulin synthesis and storage capacity of these cells. Comparison of these functional properties and corresponding cellular composition with those of clinical-grade human islet cell isolates will be indicative of the degree to which huES cell-derived implants resemble characteristics of human islet cell grafts that are known to correct diabetes in type 1 patients (14) .
RESEARCH DESIGN AND METHODS
Preparation of free and encapsulated huES cell-derived grafts. huES cell-derived pancreatic endoderm (PE) aggregates were prepared from the CyT49 cell line (5, 34) and shipped to Brussels in db medium (18) . After 16-h culture [37°C in db-N50-K50-E50 medium (5, 34)], preparations contained Ͻ10% dead cells. After sampling for cellular composition, aggregates were transplanted, free, or encapsulated. For microencapsulation, they were embedded in 1.8% alginate with high glucuronic acid (Pronova UP LVG; Novamatrix, Oslo, Norway) (28) . For macroencapsulation, they were loaded in TheraCyte devices and sealed with silicone (NuSil Technology, Carpinteria, CA). Throughout this article, the term "grafts" is used for cell preparations before transplantation and "implants" for the implanted tissue.
Pancreatic hormone levels in mice with huES cell-derived implants. Free and encapsulated grafts, each containing 4 ϫ 10 6 cells, were implanted in the subcutis or kidney capsule of nondiabetic NOD/SCID (nonobese diabetic/severe combined immune deficiency) mice (7-to 8-wk-old males, NOD.CB17-Prkdc scid /J; Charles River, L'Arbresle, France). Protocols were approved by the institutional ethics committee for animal experimentation and carried out according the European Community Council Directive (86/609/EEC). Animals were followed for 20 -30 wk with plasma taken under basal conditions (2 h following food removal) and 15 min following intraperitoneal injection of glucose (3 g/kg body wt). Proinsulin and huC-peptide were measured by trefoil-type time-resolved fluoresence immunoassay (limit of detection C-peptide 30 pM, limit of detection proinsulin 1 pM) (7), glucagon was measured by radioimmunoassay (Merck-Millipore, Billerica, MA), and blood glucose was measured by Glucocard (Menarini Diagnostics, Florence, Italy).
Data were compared with those in NOD/SCID mice receiving a cultured human islet cell graft under the kidney capsule (2 ϫ 10 6 cells, 52% insulin-positive cells). These grafts fulfilled the quality control criteria for clinical transplantation. They were provided by our Beta Cell Bank, which receives donor organs from the Eurotransplant Foundation (Leiden, The Netherlands). When quantitatively insufficient for clinical use, preparations are released for approved transplant-related studies according to the guidelines of Eurotransplant and our institutional review committee.
Cellular composition of huES cell-derived implants. At posttransplant (PT) weeks 20 -30, huES cell-derived implants were resected for histological (hematoxylin and eosin staining) and immunohistochemical analysis. Tissue was fixed in 4% phosphate-buffered formalin or Bouin (alginate capsules) before paraffin embedding. Sections underwent heat-induced antigen retrieval (2100-Retriever; Pickcell Laboratories, Lelystad, The Netherlands) in citrate buffer (Scytek Laboratories, Logan, UT) before staining with guinea pig anti-insulin (1:1,000), rabbit anti-somatostatin (1:1,000), rabbit anti-pancreatic polypeptide (1:10,000; R. E. Chance, Lilly Research, Indianapolis, IN), mouse anti-glucagon (1:4,000; Sigma-Aldrich, St. Louis, MO), mouse anti-chromogranin A (undiluted; Biogenex, Fremont, CA), mouse anti-cytokeratin 19 (1:20; Dako, Glostrup, Denmark), and mouse anti-vimentin (1:100; Dako). Secondary antibodies were F(ab=) 2 fragments of affinity-purified antibodies for multiple labeling: Alexa fluor 649-conjugated donkey anti-guinea pig, Alexa fluor 555-conjugated donkey anti-rabbit, and Alexa fluor 488-conjugated donkey anti-mouse (Jackson ImmunoResearch Laboratories, West Grove, PA). Digital images were acquired on an Axioplan 2 (Carl Zeiss, Oberkochen, Germany) microscope with an Orca-R 2 camera (Hamamatsu Photonics) and SmartCapture 3 software (DSUK, Cambridge, UK) or confocal multiphoton microscope (Zeiss LSM710 NLO with TiSa laser). Images were analyzed by SmartCapture 3 (version 3.0.8) or Zeiss Zen software. Similar analysis was conducted on formalin-fixed samples from initial huES cell-derived grafts.
Hormone synthesis, release, and content of ␣-and ␤-cells isolated from huES cell-derived implants. Tissue retrieved from devices was dispersed by collagenase (type XI; 1 mg/ml in Earle's HEPES buffer; Sigma-Aldrich, St. Louis, MO) into cell clusters (100 -500 m in diameter, as in cultured human islet cell preparations). Samples were taken to determine the number and hormone content of isolated ␣-and ␤-cells and to measure their glucose-dependent hormone release and synthesis. Data are compared with human islet cell grafts that were used in our clinical transplant program between 2008 and 2012 (n ϭ 42). These grafts had been prepared from cultures of pancreatic islet cells isolated from human donor organs (14, 16, 20) .
Total cell number was determined by nuclear count (2 g/ml, staining by propidiumiodide; Sigma-Aldrich) after cell lysis (reagent a100 and stabilization buffer; ChemoMetec, Allerød, Denmark). This number was used to calculate the numbers of glucagon-and insulin-positive cells in this preparation, with their respective percentages in immune staining considered (27) . Cellular glucagon and insulin content was calculated from these numbers and the corresponding hormone content in the preparation (27) .
Secretory responsiveness to glucose was measured by perifusing huES cell-derived or human islet cell preparations at varying glucose concentrations in the absence or presence of a glucagon supplement (20) . Insulin and glucagon were assayed in 1-min fractions and expressed as percentage of basal release (2.5 mmol/l glucose) and of cellular hormone content. The insulin biosynthetic response to glucose was determined during static 120-min incubations in the presence of L- [3, H]tyrosine (Perkin-Elmer, Boston, MA). After washing in medium with 1 mmol/l unlabeled tyrosine, cell pellets were extracted in acetic acid for the measurement of 
RESULTS

Influence of encapsulation on differentiation of huES cellderived grafts to C-peptide-releasing implants.
To assess the influence of encapsulation, huES cell-derived PE aggregates with similar cell numbers (4 ϫ 10 6 cells) were implanted in the subcutis either as nonencapsulated (free-SCi) or as macro-(macro-SCi) or microencapsulated (micro-SCi) implants. Dif-ferentiation to hormone-releasing ␤-cells was followed over 20 wk through measurements of plasma huC-peptide levels following (15 min) a glucose load. Plasma huC-peptide became detectable earlier in Theracyte macro-SCi (PT week 10) than in free-SCi (PT week 20) and rose more rapidly to higher levels ( Fig. 1A and Table 1 ), exceeding from PT week 15 onward the levels that were achieved by human ␤-cell implants under the kidney capsule (Fig. 1A) . In recipients of micro-SCi, huCpeptide levels were only marginally detectable in three of eight animals (Table 1) , insufficient for a statistically significant value at any time point (Fig. 1A) . On the other hand, their basal plasma glucagon levels were significantly higher than those in nontransplanted controls from the earliest time point onward (PT week 2). This was also the case for macro-SCi but not for free-SCi (Fig. 1B ). These differences in plasma glucagon were not associated with differences in basal glycemia among the PE recipient groups or between any of them and the nontransplanted controls (data not shown).
At PT week 20, macro-SCi exhibited basal huC-peptide levels that did not differ from those in free-SCi, but that increased significantly following glucose injection, although not in free-SCi (Table 1) . They were higher than those of free huES implants or free human islet cell implants under the kidney capsule, which did not show a statistically significant rise after a glucose load. Measurement of the concomitant plasma proinsulin (PI) levels allowed calculation of the PI/C-peptide ratio, a marker for the functional state of the ␤-cells (10). Macro-SCi exhibited the lowest ratio, which is compatible with a higher cellular reserve of converted hormone ( Table 1) .
Effect of encapsulation on endocrine differentiation in huES cell-derived implants. Implants were analyzed at PT weeks 20 -30 . Upon macroscopic inspection, the TheraCyte macrodevice exhibited a distinct vascularization of its membrane. Ingrowth of blood vessels was also seen in free implants, albeit less prominently, but not in the area of closely packed microcapsules (Fig. 2) .
Cellular composition of retrieved implants was compared with that of initial grafts (Table 2) . Initial preparations exhibited similar proportions of Pdx1-, Nkx6.1-, and Nkx2.2-positive cells, as described previously (5); ϳ25% of cells were positive for chromogranin A, with smaller fractions for CK19 or vimentin (Fig. 3) . They contained endocrine-like cells, as judged by the presence of secretory vesicles, albeit at low abundance, and positivity for insulin, glucagon, and somatostatin, some with polyhormonal expression (Fig. 4, A-C) . How- Fig. 1 . Comparison of plasma human C-peptide (huC-peptide) and glucagon levels for subcutaneous human embryonic stem (huES) cell-derived implants: nonencapsulated (free-SCi; gray circles), alginate microencapsulated (microSCi; ), and TheraCyte macroencapsulated (macro-SCi; OE). huC-peptide levels are also compared with those for human islet cell implants under the kidney capsule ({). Data are expressed as means Ϯ SD (n ϭ 4 -8). Statistical difference by 1-way ANOVA with Tukey's post hoc test: transplanted vs. non-transplanted () animals (**P Ͻ 0.01; ***P Ͻ 0.001), macroencapsulated vs. nonencapsulated huES implants (°P Ͻ 0.05;°°P Ͻ 0.01;°°°P Ͻ 0.001). Data are expressed as means Ϯ SD for 3-9 animals/group. huES, human embryonic stem; PT, posttransplant; huC-peptide, human C-peptide; PI, proinsulin; %MR, %molar ratio; hu-islet, human islet; free-SCi, nonencapsulated; micro-SCi, microencapsulated; macro-SCi, macroencapsulated; NA, not applicable. Comparison of plasma huC-peptide and PI levels in recipients of (non)encapsulated huES cell-derived grafts and hu-islet cell grafts at PT week 20. Statistical difference by 1-way ANOVA with Tukey's post hoc test. Glucose-stimulated vs. basal huC-peptide levels in the same animals:°°°P Ͻ 0.001. Plasma levels of huES recipients vs. recipients of hu-islet cell implants under the kidney capsule: †P Ͻ 0.05; † †P Ͻ 0.01; † † †P Ͻ 0.001. ever, cellular hormone content was 20-to 80-fold lower than in cultured human islet cell preparations (Table 2) .
At PT weeks 20 -30, encapsulated implants consisted predominantly of endocrine cells, with a higher degree of granulation than at the start (Fig. 4 and Table 2 ). In macro-SCi, the majority of the cells were insulin positive (46%), nearly twice the percentage of glucagon-positive cells (24%); both cell types presented a 10-fold higher hormone content than at the start (Table 2 ). Their nonendocrine cell fraction consisted of scattered vimentin-positive cells and CK19-positive cells forming small duct-like structures (Fig. 3) . Implants in a macrodevice thus exhibited a higher endocrine and ␤-cell purity than the average human islet cell graft prepared from donor pancreases. However, the mean insulin content of their ␤-cells is 42% lower (Table 2) , as is also apparent from their lower degree of granulation (Fig. 4) . In micro-SCi, glucagon-positive cells represented the major fraction (58%) with only 7% insulin-positive cells; their CK19-positive fraction was negligible (Fig. 3) , and they appeared well granulated in electron micrographs (Fig. 4) .
In nonencapsulated implants in the subcutis, the percentage of endocrine cells appeared markedly lower; their integration in host tissue interfered with its quantification. Their interstitial compartment contained numerous vimentin-positive cells, with several positive for smooth muscle actin and thus presenting a myofibroblast phenotype (data not shown). It also presented larger cystic cavities lined by CK19-positive epithelia (Fig. 3) , with some reaching a macroscopically visible size ( Fig. 2A) . No signs of teratoma were noticed.
Glucose-responsive insulin and glucagon release by ␤-and ␣-cells isolated from macroencapsulated huES cell-derived implants: comparison with responsiveness of ␤-and ␣-cells isolated from human donor pancreases. Cell preparations isolated from TheraCyte macrodevices were analyzed for their insulin and glucagon secretory responses to glucose during perifusion. Responses were expressed as percent of the release rate at basal glucose (2.5 mmol/l glucose) and compared with those in perifused human islet cell preparations. Released insulin was also expressed as percent of the cellular insulin content.
Basal insulin release (at 2.5 mmol/l glucose) from huES cell-derived ␤-cells was comparable with that from hu-islet ␤-cells (1.7 Ϯ 0.3 vs. 2.2 Ϯ 1.2 pg·1,000 ␤-cells Ϫ1 ·min Ϫ1 ). Pulses of 5, 10, and 20 mmol/l glucose induced insulin secretory responses within 1 min, but their amplitude was lower than that of hu-islet ␤-cells (Fig. 5A) . Since their cellular hormone content was also lower, this quantitative difference in secretory response became less pronounced when release was expressed as function of cellular insulin content (Fig. 5B) . Addition of glucagon at 20 mmol/l glucose amplified release in both preparations to the same extent. Replacing the stimulatory glucose concentration by 2.5 mmol/l glucose resulted in rapid return of insulin release to basal rates.
Basal glucagon release from huES cell-derived ␣-cells was also similar to that from hu-islet ␣-cells (0.6 Ϯ 0.1 vs. 0.9 Ϯ 0.3 pg·1,000 ␣-cells Ϫ1 ·min Ϫ1 ). It was suppressed by increasing glucose concentrations to the same extent in both preparations (Fig. 5C ). 
Insulin synthesis capacity of ␤-cells isolated from macroencapsulated huES cell-derived implants: comparison with ␤-cells isolated from human donor pancreases.
In a subsequent study, we measured the insulin synthesis capacity of huES cell-derived ␤-cells retrieved from macrodevices. Initial grafts were prepared from aggregates shipped under cryopreserved form; they fulfilled the same quality control criteria as fresh cells. Rates of newly synthesized insulin were expressed per 10 3 ␤-cells per hour and compared with the amounts synthesized by hu-islet ␤-cells under similar incubation conditions. In the absence of glucose, huES cell-derived ␤-cells exhibited a rate that was not different from that in cultured pancreatic ␤-cell isolates (Table 3) . They responded to glucose (10 mmol/l) with a significantly increased rate, but the net glucose effect was significantly lower.
DISCUSSION
Our clinical islet cell transplant program prepares grafts from cultured human islet cell isolates with defined cellular composition (14, 16) . ␤-Cell number and endocrine purity of cultured rat and human islet cell grafts influence the outcome in rodents (11, 15, 25) . Clinical data confirm the significance of determining ␤-cell number (14) , but so far the benefit of high endocrine purity could not be assessed because of the inability to prepare sufficiently large grafts that meet this criterion. Islet cell preparations with known composition also allow analysis of functions on a cellular basis (16, 20) . Data on composition and function of human islet cell preparations can serve as a reference for grafts that induce metabolic correction in C-peptide-negative patients. They also help to assess the therapeutic potential of stem cell-derived ␤-cell preparations and the significance of their molecular characterization (17) . Reports on huC-peptide-secreting implants following transplantation of huES cell-derived grafts (2, 8, 18, 30) led us to compare composition and function of these implants with our clinicalgrade human islet cell grafts.
Our study was conducted with grafts derived from the huES CyT49 cell line of ViaCyte. Initial derivations involved a five-stage differentiation protocol leading to formation of insulin-positive cells in vitro (4, 5) . In view of their polyhormonal content and glucose unresponsiveness, the PE-enriched fraction at stage 4 was retrieved and transplanted in immunedeficient mice, where they further differentiated to singlehormone-positive islet cells but also to cells with features of http://ajpendo.physiology.org/ pancreatic acinar and duct cells and cells of nonendodermal origin; signs of teratoma were noticed in 15% of recipients (18) . Plasma huC-peptide levels increased with time to levels (Ͼ0.7 nmol/l) that protected against diabetes when recipient ␤-cells were destroyed by streptozotocin (18) . These levels are in the range of those that correct diabetes in mouse recipients of human islet cell grafts (25) .
Quality-controlled PE aggregates were shipped from ViaCyte to Brussels, Belgium. At implantation they contained Յ25% pancreatic hormone-positive cells, mostly polyhormonal. Hormone content of insulin-and glucagon-positive cells was 20-fold lower than that in ␤-and ␣-cells of human pancreatic isolates. Similar cells have been observed in the midgestational human fetal pancreas (12-18 wk) but not in neonates (6, 32) ; their biological significance is still unclear. Differentiation to hormone releasing implants was followed in free and micro-and macroencapsulated grafts containing the same cell number (1.6 ϫ 10 8 cells/kg body wt) and implanted in the subcutis. The appearance of huC-peptide in plasma indicated that differentiation to hormone-releasing ␤-cells proceeded faster in TheraCyte macroimplants than in free implants. The rise in its concentration over the following 10 wk might have resulted from formation of more ␤-cells and/or maturation of new ␤-cells to a functional state with higher release rates. At PT week 20, huC-peptide levels were glucose responsive and higher than those observed for human islet cell implants containing 0.8 to 2.5 ϫ 10 8 cells/kg body wt (25) . This was associated with a lower proinsulin/C-peptide ratio that is indicative of a higher cellular reserve in converted hormone. However, these in vivo characteristics are insufficient to conclude that the ␤-cells formed in macro-SCi have reached a functionally mature stage. To address this question, the cells were retrieved for ex vivo analysis and compared with isolated human islet cell preparations, as used for clinical transplantation. Tissue isolated from the macrodevices presented a higher endocrine purity than free implants, which contained more myofibroblasts and CK19-positive epithelia, lining cavities of variable size. Its endocrine cells were singlehormone-positive and present in proportions that are comparable with those in the endocrine pancreas of human neonates with a majority of ␤-cells and equally high percentages of glucagon-and somatostatin-positive cells (29) . Alginatemicroencapsulated implants were also enriched in endocrine cells, but these corresponded mainly to single glucagon-positive cells. Their low-percentage insulin-positive cells did not result in any significant huC-peptide levels in the plasma. Interestingly, recipients of both macro-and micro-SCi exhibited an early and persistent rise in basal plasma glucagon levels. This rise might reflect release from glucagon-positive cells in the implant and perhaps those that were already present in the initial grafts. However, our glucagon assay does not distinguish human from mouse glucagon, so their respective contribution cannot be determined. The differences in endocrine composition between macro-and micro-SCi may be related to differences in cell packing or in vascularization. Ex vivo analysis of macro-SCi is facilitated by the ability to quantitatively retrieve living cells from the devices without contamination by the host tissue. The present study focused on glucose-regulated insulin synthesis and release by newly formed ␤-cells, as this property is of key physiological importance. huES cell-derived ␤-cells rapidly elevated or suppressed their insulin secretion in response to increases or decreases in glucose concentration, with similar kinetics as human islet ␤-cells. However, their average release, as expressed per 10 3 ␤-cells, was smaller. This difference is in part attributable to the lower cellular content of newly formed ␤-cells and in part to a weaker glucose-induced signaling. Indeed, glucose-inducible insulin biosynthesis was also lower in huES-generated ␤-cells than in human ␤-cell isolates, whereas their basal rates were similar. On the other hand, the secretory response to glucagon was equally potent in both preparations. Taken together, these functional data support the view that huESgenerated ␤-cells have not yet fully matured at PT week 20 (9, 12, 22, 26) . When comparing glucose responsiveness of huESderived ␣-cells with that of ␣-cells in human islet cell isolates, no differences were seen; both preparations rapidly suppressed their glucagon release during glucose pulses and returned to higher levels in between; the amplitude of these responses was similar. Newly formed ␣-cells may thus have reached a higher maturation stage than the ␤-cells. It is conceivable that their locally released hormones influence differentiation of neighboring ␤-cells (15, 19, 21, 26) .
Similar circulating C-peptide levels were reached by nonencapsulated huES-derived implants in nude rats (unpublished data), which indicates that differentiation to functional ␤-cells is also reached in other species; differences in cell preparation and experimental conditions may explain the failures that were observed previously in these animals (23) . Since our data have been collected only for grafts derived from the CyT49 cell line of ViaCyte, it could be argued that they are not necessarily representative for huES-generated implants. However, multiple huES cell lines were shown to generate ␤-cells, following protocols that are largely comparable with and/or based on Viacyte's methods, some requiring optimization, particularly in view of undifferentiated growth. It is likely that ␤-cells derived from different sources have the capability of exhibiting similar properties but can vary in functional differentiation, depending on time, local microenvironment, and general metabolic state. In vivo data can be indicative for functional differences between implants from different sources, provided they are collected from grafts with similar cell number and composition. However, they cannot distinguish whether circulating signs for an increased functional ␤-cell mass are attributable to increased neoformation or proliferation of ␤-cells or a higher stage of functional maturation. Such distinction requires ex vivo analysis of the ␤-cell population in the implant. In this study, standardized in vitro methods were used for evaluating glucose regulation of huES-derived endocrine cells. They aid in preclinical determinations of safety, efficacy, and dosing and represent unbiased benchmarks against which other cell preparations can be measured, regardless of their source and differentiation protocol. Since the first clinical trials will probably be conducted with subtherapeutic doses, they may also prove to be invaluable tools to assess outcome.
It is concluded that macroencapsulation of huES cell-derived PE cells favors their differentiation to pancreatic endocrine cells. At PT week 20, endocrine purity of the implants is higher than that of clinical-grade human islet cell grafts. Their composition and functions are compatible with an early differen- Comparison of huES-cell derived implants retrieved from macro-SCi at PT weeks 20 -30 with human islet cell preparations. Data are expressed as means Ϯ SD, statistical difference by Student's t-test: 10 mmol/l vs 0 mmol/l glucose (*P Ͻ 0.05, ***P Ͻ 0.001) and huES cell-derived cells vs. hu-islet cells ( † †P Ͻ 0.01). 20 -30 (n ϭ 3) and human islet cell isolates (n ϭ 6) were perifused at different glucose concentrations with and without 10 Ϫ8 mol/l glucagon. Insulin release was expressed as %basal release (2.5 mmol/l glucose) and %cellular insulin content (means Ϯ SD). Responses to 5, 10, or 20 mmol/l glucose were determined as the average of the 3 highest consecutive values and compared (Student t-test) with basal release (*P Ͻ 0.05; **P Ͻ 0.01; ***P Ͻ 0.001) and with the response of human islet cell preparations (°°P Ͻ 0.01;°°°P Ͻ 0.001). Glucagon release was expressed as %basal release and its response to glucose as the lowest glucagon value. tiation and maturation stage. Newly formed ␤-cells respond rapidly to changes in glucose concentration, but amplitudes are smaller than in human islet cell preparations, as is also their insulin content. Analysis of implants at later time points can indicate whether they develop into a mature ␤-cell mass in which number and functional state of ␤-cells can adapt to metabolic needs; however, such study is limited by the lifespan of the mice. Endocrine differentiation will probably also be influenced by the microenvironment and thus differ for cells packed with other cells in subcutaneous devices than for the smaller, dispersed, and well-vascularized endocrine cell aggregates in the pancreas. Although the higher cellular insulin content of pancreatic ␤-cells can be seen as a functional reserve needed to meet prolonged or excessive hormone demands, it is not excluded that development of an insulin-producing implant in an ectopic site can achieve a metabolically adequate ␤-cell mass with ␤-cells that exhibit different properties. Combined in vivo, in situ and ex vivo studies of implants can gain insights in this process. These will be more relevant when conducted in man than in animals, but the latter can also be informative in a prior stage in terms of the criteria to be met before clinical translation.
ACKNOWLEDGMENTS
We thank our collaborators at the Diabetes Research Center-Vrije Universiteit Brussel and Universitair Ziekenhuis Brussel (Belgium) for their scientific, technical, and administrative support. 
GRANTS
AUTHOR CONTRIBUTIONS
E.M., E.S., and D.P. analyzed data; E.M., E.S., K.S., G.S., Z.L., E.K., and D.P. interpreted results of experiments; E.M. prepared figures; E.M. and D.P. drafted manuscript; E.M., K.S., G.S., D.J.-TT., Z.L., E.K., and D.P. approved final version of manuscript; E.S., K.S., M.B., D.J.-TT., Z.L., E.K., and D.P. conception and design of research; E.S., K.S., M.B., and D.J.-TT. performed experiments; E.M., K.S., G.S., D.J.-TT., Z.L., E.K., and D.P. edited and revised manuscript.
